Production (Stage)
Orchestra BioMed Holdings, Inc.
OBIO
$2.72
-$0.01-0.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.32M | -61.02M | -57.69M | -55.58M | -51.64M |
| Total Depreciation and Amortization | 317.00K | 308.00K | 296.00K | 291.00K | 290.00K |
| Total Amortization of Deferred Charges | 77.00K | 31.00K | 3.00K | 39.00K | 76.00K |
| Total Other Non-Cash Items | 11.78M | 10.89M | 8.91M | 8.94M | 7.14M |
| Change in Net Operating Assets | 79.00K | -765.00K | 482.00K | 1.73M | -725.00K |
| Cash from Operations | -54.06M | -50.56M | -47.99M | -44.58M | -44.86M |
| Capital Expenditure | -393.00K | -289.00K | -180.00K | -131.00K | -51.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -602.00K | -602.00K | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.22M | 13.98M | 50.17M | 62.51M | 60.13M |
| Cash from Investing | 20.23M | 13.09M | 49.99M | 62.38M | 60.08M |
| Total Debt Issued | 15.00M | 15.00M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -10.85M | -10.85M | -10.85M |
| Issuance of Common Stock | 15.35M | 15.28M | 15.38M | 346.00K | 261.00K |
| Repurchase of Common Stock | -937.00K | -550.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -554.00K | -554.00K | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 28.86M | 29.17M | 4.53M | -10.50M | -10.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.98M | -8.30M | 6.53M | 7.30M | 4.63M |